Related Experiment Video
Updated: Jan 21, 2026

Assessing Specificity of Anticancer Drugs In Vitro
Published on: March 23, 2016
Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma
Debora Basile1,2, Camilla Lisanti1,2, Maria A Pizzichetta2,3
1Department of Medicine, University of Udine, Udine 33100, Italy.
Background:
Malignant melanoma is a skin cancer responsible for 90% of cutaneous cancer- related deaths. In recent years, breakthroughs in treatment strategy have revolutionized the prognosis in both early and advanced melanoma patients. In particular, treatment with monoclonal antibodies targeting co-inhibitory checkpoints or specific molecular pathways leads to a new era of promising options, by prolonging the survival time of these patients. Moreover, unlike the chemotherapy that was used until some time ago, these new drugs have a good and more manageable toxicity profile. However, because of the recent introduction in clinical practice of the new agents, there is a learning curve among physicians regarding early recognition and management of the associated side effects.
Objectives:
The analysis of the toxicity profiles of the different agents currently studied for the treatment of early and advanced melanoma, and the description of several relevant recent patents in this field, are the aims of this review.
Methods:
This is a systematically conducted review based on current clinical guidelines and on international Pharmacovigilance databases (AERS-Eudravigilance - WHO Vigibase).
Results:
Our systematic analysis outlines a comprehensive overview of the pharmacology, clinical application and the safety of recent anticancer drugs to treat melanoma, which can be an essential instrument for health professionals and researchers.
Conclusion:
The new oncological therapies against melanoma are based on increasingly specific biological and immunological targets. For this reason, the potential toxicities that are expected from patients would be less relevant than the systemic "classical" chemotherapy. However, the new therapies are not free from the risk of causing adverse reactions, some of which must be managed promptly and appropriately; moreover, the multiplicity of the metabolic pathways exposes the new target therapies to relevant potential interactions. This review can help to understand how important it is not to underestimate potential adverse drug reactions related to new targeted therapies.
Insights
New melanoma treatments offer improved survival but require careful management of potential side effects. Understanding adverse drug reactions is crucial for healthcare professionals using these targeted therapies.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Malignant melanoma is a deadly skin cancer with recent treatment advances improving patient prognosis.
- Novel therapies, including monoclonal antibodies, offer promising survival benefits for early and advanced melanoma.
- These newer agents present a more manageable toxicity profile compared to traditional chemotherapy.
Purpose of the Study:
- To analyze the toxicity profiles of current early and advanced melanoma treatments.
- To review recent patents related to melanoma therapeutics.
- To provide an essential resource for health professionals and researchers.
Main Methods:
- Systematic review of current clinical guidelines.
- Analysis of international Pharmacovigilance databases (AERS-Eudravigilance, WHO Vigibase).
Main Results:
- Comprehensive overview of the pharmacology, clinical application, and safety of recent melanoma anticancer drugs.
- Highlights the essential role of this analysis for healthcare providers and researchers.
- Provides insights into the safety and efficacy of novel melanoma treatments.
Conclusions:
- Modern melanoma therapies target specific biological and immunological pathways, potentially reducing toxicity compared to chemotherapy.
- New targeted therapies are associated with adverse reactions that require prompt and appropriate management.
- Potential drug interactions due to multiple metabolic pathways necessitate careful consideration with new targeted therapies.
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Dissolution: Requirements and Profile Comparison
Survey Safety
Design Consideration
The factor of safety is another key...
Tensile Strength Considerations of Concrete
The dimensions and shape of a concrete specimen...
Transmission Line Design Considerations

